ArriVent Biopharma, Inc. executed one of the first initial public offerings by a biopharmaceutical company in the US this year, primarily to fund its lead drug candidate firmonertinib, an EGFR tyrosine kinase inhibitor (TKI) in Phase III as a first-line monotherapy for non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. Now, the company has reported Phase Ib results in NSCLC patients with hard-to-treat PACC mutations, a larger patient population.
ArriVent Targets PACC Mutation Market With EGFR TKI Firmonertinib In Lung Cancer
Drug Shows CNS Activity In Early Trial
Newly public company ArriVent BioPharma presented Phase Ib results at WCLC for its kinase inhibitor, which could be the first drug available specifically for hard-to-treat PACC mutations.
More from Clinical Trials
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
More from R&D
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.